Den kliniske gevinst, bedømt efter samlet overlevelse, blev set i alle forudspecificerede patientundergrupper, inklusive grupper defineret iht. alder, køn, performance status, lokalisering af primær tumor, antal involverede organer og varighed af metastatisk sygdom.
The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease.